A Phase 2 interventional study of Placebo and Risankizumab in Dermatitis, sponsored by AbbVie. Completed at 65 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-18.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Dermatitis, Atopic by AbbVie — 3 open to participants now, 12 under way, 4 of them phase 3. Dermatitis, Atopic · AbbVie.
Among the 34 studies in Dermatitis, Atopic by AbbVie, this one is the 13th largest by enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2018, is one of 6 in phase 2, and was the 7th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →3 of the 34 studies in Dermatitis, Atopic by AbbVie are open now, in 9 countries. Recruiting first, the newest first:
Apogee Therapeutics, Inc. · Sites in United States, Canada, Czechia and 6 more countries
Ages 18+
AbbVie · Sites in United States
Ages 18–75
AbbVie
Ages 18–64
By country, each count listing its studies:
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 172 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 228 across the 22 interventional studies, 300 across the 11 observational. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
7 of the studies in Dermatitis, Atopic by AbbVie that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT06701331Phase 3AbbVieSafety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis | 2027-01 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
| NCT05669794AbbVieAn Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World | 2027-02 |
| NCT06524635AbbVieA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab | 2027-02 |
Add all 7 to your calendar (.ics) → With an account.
Among the 34 studies in Dermatitis, Atopic by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of risankizumab for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents.
This study includes a screening period of up to 35 days, a 16-week double-blind treatment period (Period A), and a 36-week double-blind treatment period (Period B).
Participants who meet eligibility criteria will be randomized at Baseline in a 2:2:1 ratio to one of 3 treatment groups: (1) risankizumab 150 mg, (2) risankizumab 300 mg, or (3) matching placebo. Randomization will be stratified by Baseline disease severity (Validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of moderate [3] versus severe [4]) and geographic region (Japan versus rest of world).
At Week 16, participants in the placebo group will be re-randomized in a 1:1 ratio to receive either risankizumab 150 mg or 300 mg for the remainder of the study. Participants originally randomized to the risankizumab 150 mg or 300 mg arms will stay on their previously-assigned treatment through the end of the study.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
This study's enrollment of 172 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Compared within Dermatitis, Atopic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dermatitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive placebo for 16 weeks in Period A followed by either risankizumab 150 mg or risankizumab 300 mg for 36 weeks in Period B.
Biological: Placebo · Biological: Risankizumab
Participants randomized to receive risankizumab 150 mg for 16 weeks in Period A followed by risankizumab 150 mg for 36 weeks in Period B.
Biological: Risankizumab
Participants randomized to receive risankizumab 300 mg for 16 weeks in Period A followed by risankizumab 300 mg for 36 weeks in Period B.
Biological: Risankizumab
subcutaneous (SC) injection
subcutaneous (SC) injection
Also known as: ABBV-066, BI 655066
Percentage of Participants Achieving At Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Time frame: Baseline and Week 16
Percentage of Participants Who Achieved a vIGA-AD Score of "0" or "1" With a Reduction From Baseline of ≥ 2 Points at Week 16
Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) was used to assess the severity of AD based on lesion appearance on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.
Time frame: Baseline and Week 16
Percentage of Participants Who Achieved a Reduction of ≥ 4 Points in Worst Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Time frame: Baseline and Week 16
Percent Change From Baseline in EASI Score at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
Time frame: Baseline and Week 16
Percent Change From Baseline in EASI Score at Week 28 and Week 52
EASI is used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected and the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling), scratching, and lichenification (lined skin, prurigo nodules). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement. LS means were calculated from an analysis of covariance (ANCOVA) model with Baseline, treatment and vIGA-AD categories in the model.
Time frame: Baseline and Weeks 28 and 52
Percentage of Participants Who Achieved an EASI 75 Response at Week 28 and Week 52
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Time frame: Baseline and Weeks 28 and 52
Percentage of Participants Who Achieved an EASI 50 Response at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. EASI 50 response is defined as at least a 50% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline and Week 16
Percentage of Participants Who Achieved an EASI 50 Response at Week 28 and Week 52
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 50 response is defined as at least a 50% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline and Weeks 28 and 52
Percentage of Participants Who Achieved an EASI 90 Response at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline, Week 16
Percentage of Participants Who Achieved an EASI 90 Response at Week 28 and Week 52
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline and Weeks 28 and 52
Percentage of Participants Who Achieved a vIGA-AD Score of "0" or "1" With a Reduction From Baseline of ≥ 2 Points at Week 28 and Week 52
Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) was used to assess the severity of AD based on lesion appearance on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.
Time frame: Baseline and Weeks 28 and 52
Change From Baseline in Percentage of Body Surface Area (BSA) Affected by Atopic Dermatitis at Week 16
Body surface area (BSA) affected by atopic dermatitis was assessed by the physician and is expressed as a percentage of the total BSA. For purposes of the estimation, the total surface of the participant's palm plus five digits was assumed to be approximately equivalent to 1% BSA. A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 16
Change From Baseline in Percentage of BSA Affected by Atopic Dermatitis at Weeks 28 and 52
Body surface area (BSA) affected by atopic dermatitis was assessed by the physician and is expressed as a percentage of the total BSA. For purposes of the estimation, the total surface of the participant's palm plus five digits was assumed to be approximately equivalent to 1% BSA. A negative change from Baseline indicates improvement. LS means and standard errors were calculated from ANCOVA with Baseline, treatment and stratum (Baseline vIGA-AD categories) in the model.
Time frame: Baseline and Weeks 28 and 52
Percentage of Participants Who Achieved a 50% Improvement in SCORing Atopic Dermatitis (SCORAD) Score (SCORAD 50) at Week 16
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst).
Time frame: Baseline, Week 16
Percentage of Participants Who Achieved a SCORAD 50 Response at Week 28 and Week 52
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst).
Time frame: Baseline and Weeks 28 and 52
Percentage of Participants Who Achieved a SCORAD 75 Response at Week 16
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 75 response is defined as at least a 75% reduction (improvement) from Baseline in SCORAD score.
Time frame: Baseline and Week 16
Percentage of Participants Who Achieved a SCORAD 75 Response at Week 28 and Week 52
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 75 response is defined as at least a 75% reduction (improvement) from Baseline in SCORAD score.
Time frame: Baseline and Weeks 28 and 52
Percentage of Participants Who Achieved a SCORAD 90 Response at Week 16
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 90 response is defined as at least a 90% reduction (improvement) from Baseline in SCORAD score.
Time frame: Baseline and Week 16
Percentage of Participants Who Achieved a SCORAD 90 Response at Week 28 and Week 52
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 90 response is defined as at least a 90% reduction (improvement) from Baseline in SCORAD score.
Time frame: Baseline and Weeks 28 and 52
Percentage of Participants Who Achieved a Dermatology Life Quality Index (DLQI) Score of "0" or "1" at Week 16
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all.
Time frame: Week 16
Percentage of Participants Who Achieved a DLQI Score of "0" or "1" at Week 28 and Week 52
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all.
Time frame: Weeks 28 and 52
Percentage of Participants Who Achieved a Children's Dermatology Life Quality Index (CDLQI) Score of "0" or "1" at Week 16
The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. In this study, the CDLQI was administered to participants who were \< 16 years old at Baseline.
Time frame: Week 16
Percentage of Participants Who Achieved a CDLQI Score of "0" or "1" at Week 28 and Week 52
The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. In this study, the CDLQI was administered to participants who were \< 16 years old at Baseline.
Time frame: Weeks 28 and 52
Percentage of Participants Who Achieved a Reduction in DLQI of ≥ 4 Points From Baseline at Week 16 Among Those With a DLQI ≥ 4 at Baseline
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A change in DLQI score of at least 4 points is considered the minimum clinically important difference (MCID).
Time frame: Baseline and Week 16
Percentage of Participants Who Achieved a Reduction in DLQI of ≥ 4 Points From Baseline at Week 28 and Week 52 Among Those With a DLQI ≥ 4 at Baseline
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A change in DLQI score of at least 4 points is considered the minimum clinically important difference (MCID).
Time frame: Baseline and Weeks 28 and 52
Change From Baseline in DLQI Score at Week 16
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 16
Change From Baseline in DLQI Score at Week 28 and Week 52
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A negative change from Baseline indicates improvement. LS means and standard errors were calculated from an ANCOVA model with Baseline, treatment and stratum (Baseline vIGA-AD categories) in the model.
Time frame: Baseline and Weeks 28 and 52
Change From Baseline in CDLQI Score at Week 16
The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A negative change from Baseline indicates improvement. In this study, the CDLQI was administered to participants who were \< 16 years old at the Baseline visit.
Time frame: Baseline and Week 16
Change From Baseline in CDLQI Score at Week 28 and Week 52
The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A negative change from Baseline indicates improvement. In this study, the CDLQI was administered to participants who were \< 16 years old at the Baseline visit. LS means were calculated from ANCOVA with Baseline and treatment in the model.
Time frame: Baseline and Weeks 28 and 52
Change From Baseline in Worst Pruritus Numerical Rating Scale at Week 16
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Change from Baseline was calculated from a rolling weekly average. A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 16
Change From Baseline in Worst Pruritus NRS Score at Week 28 and Week 52
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Change from Baseline was calculated from a rolling weekly average. A negative change from Baseline indicates improvement. LS means and standard errors were calculated from an ANCOVA with Baseline, treatment and stratum (Baseline vIGA-AD categories) in the model.
Time frame: Baseline and Weeks 28 and 52
Percentage of Participants Who Achieved a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS Score at Week 28 and Week 52
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Time frame: Baseline and Weeks 28 and 52
Adults and adolescents with moderate to severe atopic dermatitis (AD) with onset of symptoms at least 2 years before the Baseline visit were enrolled at 50 sites in the United States, Canada, Japan, and Australia. The study included a 16-week double-blind treatment period (Period A) followed by a 36-week double-blind treatment period (Period B).
| Milestone | Period A: Placebo | Period A: Risankizumab 150 mg | Period A: Risankizumab 300 mg | Period B: Placebo / Risankizumab 150 mg | Period B: Placebo / Risankizumab 300 mg | Period B: Risankizumab 150 mg / Risankizumab 150 mg | Period B: Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|---|---|---|
| Started | 34 | 69 | 69 | 0 | 0 | 0 | 0 |
| Received study drug | 34 | 69 | 69 | 0 | 0 | 0 | 0 |
| Completed | 25 | 61 | 58 | 0 | 0 | 0 | 0 |
| Not completed | 9 | 8 | 11 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 3 | 5 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 2 | 0 | 2 | 0 | 0 | 0 | 0 |
| Milestone | Period A: Placebo | Period A: Risankizumab 150 mg | Period A: Risankizumab 300 mg | Period B: Placebo / Risankizumab 150 mg | Period B: Placebo / Risankizumab 300 mg | Period B: Risankizumab 150 mg / Risankizumab 150 mg | Period B: Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 13 | 12 | 61 | 58 |
| Received study drug | 0 | 0 | 0 | 13 | 11 | 61 | 57 |
| Completed | 0 | 0 | 0 | 5 | 3 | 33 | 30 |
| Not completed | 0 | 0 | 0 | 8 | 9 | 28 | 28 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 2 | 3 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 3 | 2 | 1 | 10 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 4 | 5 | 23 | 17 |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
| percentage of participants | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Percentage of Participants Achieving At Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) at Week 16 | 11.8 (0.9 to 22.6) | 24.6 (14.5 to 34.8) | 21.7 (12.0 to 31.5) |
Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) was used to assess the severity of AD based on lesion appearance on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.
| percentage of participants | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a vIGA-AD Score of "0" or "1" With a Reduction From Baseline of ≥ 2 Points at Week 16 | 5.9 (0.0 to 13.8) | 14.5 (6.2 to 22.8) | 5.8 (0.3 to 11.3) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
| percentage of participants | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a Reduction of ≥ 4 Points in Worst Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16 | 0 (NA to NA) | 13.6 (5.4 to 21.9) | 15.2 (6.5 to 23.8) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
| percent change | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Percent Change From Baseline in EASI Score at Week 16 | -28.54 ± 9.378 | -38.86 ± 5.989 | -45.39 ± 6.351 |
EASI is used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected and the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling), scratching, and lichenification (lined skin, prurigo nodules). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement. LS means were calculated from an analysis of covariance (ANCOVA) model with Baseline, treatment and vIGA-AD categories in the model.
| percent change | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | -58.60 ± 12.091 | -59.81 ± 14.956 | -62.44 ± 5.065 | -63.77 ± 5.051 |
| Week 52 | -31.39 ± 12.979 | -76.75 ± 14.199 | -67.47 ± 4.663 | -62.70 ± 4.875 |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
| percentage of participants | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | 37.5 (4.0 to 71.0) | 0 (NA to NA) | 53.3 (38.8 to 67.9) | 41.9 (27.1 to 56.6) |
| Week 52 | 0 (NA to NA) | 75.0 (32.6 to 100.0) | 43.2 (27.3 to 59.2) | 45.5 (28.5 to 62.4) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. EASI 50 response is defined as at least a 50% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved an EASI 50 Response at Week 16 | 29.4 (14.1 to 44.7) | 42.0 (30.4 to 53.7) | 34.8 (23.5 to 46.0) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 50 response is defined as at least a 50% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | 75.0 (45.0 to 100.0) | 80.0 (44.9 to 100.0) | 73.3 (60.4 to 86.3) | 74.4 (61.4 to 87.5) |
| Week 52 | 40.0 (0.0 to 82.9) | 75.0 (32.6 to 100.0) | 78.4 (65.1 to 91.6) | 72.7 (57.5 to 87.9) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved an EASI 90 Response at Week 16 | 2.9 (0.0 to 8.6) | 14.5 (6.2 to 22.8) | 8.7 (2.0 to 15.3) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | 25.0 (0.0 to 55.0) | 0 (NA to NA) | 26.7 (13.7 to 39.6) | 27.9 (14.5 to 41.3) |
| Week 52 | 0 (NA to NA) | 0 (NA to NA) | 24.3 (10.5 to 38.1) | 18.2 (5.0 to 31.3) |
Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) was used to assess the severity of AD based on lesion appearance on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.
| percentage of participants | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | 0 (NA to NA) | 0 (NA to NA) | 22.2 (10.1 to 34.4) | 25.6 (12.5 to 38.6) |
| Week 52 | 0 (NA to NA) | 0 (NA to NA) | 24.3 (10.5 to 38.1) | 21.2 (7.3 to 35.2) |
Body surface area (BSA) affected by atopic dermatitis was assessed by the physician and is expressed as a percentage of the total BSA. For purposes of the estimation, the total surface of the participant's palm plus five digits was assumed to be approximately equivalent to 1% BSA. A negative change from Baseline indicates improvement.
| percentage of body surface area | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Change From Baseline in Percentage of Body Surface Area (BSA) Affected by Atopic Dermatitis at Week 16 | -7.41 ± 3.813 | -13.64 ± 2.429 | -13.27 ± 2.569 |
Body surface area (BSA) affected by atopic dermatitis was assessed by the physician and is expressed as a percentage of the total BSA. For purposes of the estimation, the total surface of the participant's palm plus five digits was assumed to be approximately equivalent to 1% BSA. A negative change from Baseline indicates improvement. LS means and standard errors were calculated from ANCOVA with Baseline, treatment and stratum (Baseline vIGA-AD categories) in the model.
| percentage of body surface area | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | -20.07 ± 5.843 | -11.90 ± 7.294 | -23.23 ± 2.438 | -23.22 ± 2.443 |
| Week 52 | -0.86 ± 6.525 | -30.23 ± 7.316 | -29.26 ± 2.400 | -22.14 ± 2.510 |
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst).
| percentage of participants | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a 50% Improvement in SCORing Atopic Dermatitis (SCORAD) Score (SCORAD 50) at Week 16 | 18.0 (5.0 to 31.1) | 24.6 (14.5 to 34.8) | 13.0 (5.1 to 21.0) |
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst).
| percentage of participants | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | 44.4 (12.0 to 76.9) | 20.0 (0.0 to 55.1) | 47.8 (33.4 to 62.3) | 37.2 (22.8 to 51.7) |
| Week 52 | 0 (NA to NA) | 50.0 (1.0 to 99.0) | 52.6 (36.8 to 68.5) | 35.1 (19.8 to 50.5) |
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 75 response is defined as at least a 75% reduction (improvement) from Baseline in SCORAD score.
| percentage of participants | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a SCORAD 75 Response at Week 16 | 0 (NA to NA) | 10.1 (3.0 to 17.3) | 2.9 (0.0 to 6.9) |
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 75 response is defined as at least a 75% reduction (improvement) from Baseline in SCORAD score.
| percentage of participants | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | 11.1 (0.0 to 31.6) | 0 (NA to NA) | 23.9 (11.6 to 36.2) | 11.6 (2.0 to 21.2) |
| Week 52 | 0 (NA to NA) | 0 (NA to NA) | 21.1 (8.1 to 34.0) | 13.5 (2.5 to 24.5) |
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 90 response is defined as at least a 90% reduction (improvement) from Baseline in SCORAD score.
| percentage of participants | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a SCORAD 90 Response at Week 16 | 0 (NA to NA) | 5.8 (0.3 to 11.3) | 1.4 (0.0 to 4.3) |
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 90 response is defined as at least a 90% reduction (improvement) from Baseline in SCORAD score.
| percentage of participants | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | 0 (NA to NA) | 0 (NA to NA) | 6.5 (0.0 to 13.7) | 4.7 (0.0 to 10.9) |
| Week 52 | 0 (NA to NA) | 0 (NA to NA) | 15.8 (4.2 to 27.4) | 10.8 (0.8 to 20.8) |
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all.
| percentage of participants | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a Dermatology Life Quality Index (DLQI) Score of "0" or "1" at Week 16 | 9.0 (0.0 to 18.8) | 8.7 (2.0 to 15.3) | 5.8 (0.3 to 11.3) |
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all.
| percentage of participants | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | 22.2 (0.0 to 49.4) | 20.0 (0.0 to 55.1) | 16.3 (6.0 to 26.7) | 13.6 (3.5 to 23.8) |
| Week 52 | 20.0 (0.0 to 55.1) | 25.0 (0.0 to 67.4) | 13.9 (2.6 to 25.2) | 15.6 (3.0 to 28.2) |
The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. In this study, the CDLQI was administered to participants who were \< 16 years old at Baseline.
| percentage of participants | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a Children's Dermatology Life Quality Index (CDLQI) Score of "0" or "1" at Week 16 | — | 0 | 0 |
The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. In this study, the CDLQI was administered to participants who were \< 16 years old at Baseline.
| percentage of participants | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | — | — | 0 | — |
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A change in DLQI score of at least 4 points is considered the minimum clinically important difference (MCID).
| percentage of participants | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a Reduction in DLQI of ≥ 4 Points From Baseline at Week 16 Among Those With a DLQI ≥ 4 at Baseline | 25.6 (10.3 to 41.0) | 31.3 (19.9 to 42.6) | 37.5 (25.6 to 49.4) |
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A change in DLQI score of at least 4 points is considered the minimum clinically important difference (MCID).
| percentage of participants | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | 77.8 (50.6 to 100.0) | 40.0 (0.0 to 82.9) | 66.7 (52.9 to 80.4) | 68.3 (54.0 to 82.5) |
| Week 52 | 60.0 (17.1 to 100.0) | 50.0 (1.0 to 99.0) | 63.6 (47.2 to 80.0) | 66.7 (49.8 to 83.5) |
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A negative change from Baseline indicates improvement.
| score on a scale | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Change From Baseline in DLQI Score at Week 16 | -3.4 ± 1.55 | -3.4 ± 0.95 | -4.4 ± 1.03 |
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A negative change from Baseline indicates improvement. LS means and standard errors were calculated from an ANCOVA model with Baseline, treatment and stratum (Baseline vIGA-AD categories) in the model.
| score on a scale | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | -8.0 ± 2.06 | -5.3 ± 2.69 | -7.1 ± 0.87 | -7.3 ± 0.93 |
| Week 52 | -4.5 ± 2.99 | -5.0 ± 3.30 | -7.7 ± 1.11 | -6.5 ± 1.18 |
The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A negative change from Baseline indicates improvement. In this study, the CDLQI was administered to participants who were \< 16 years old at the Baseline visit.
| score on a scale | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Change From Baseline in CDLQI Score at Week 16 | — | -2.0 ± NA | — |
The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A negative change from Baseline indicates improvement. In this study, the CDLQI was administered to participants who were \< 16 years old at the Baseline visit. LS means were calculated from ANCOVA with Baseline and treatment in the model.
| score on a scale | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | — | — | 1.0 ± 0.00 | — |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Change from Baseline was calculated from a rolling weekly average. A negative change from Baseline indicates improvement.
| score on a scale | Placebo | Risankizumab 150 mg | Risankizumab 300 mg |
|---|---|---|---|
| Change From Baseline in Worst Pruritus Numerical Rating Scale at Week 16 | -0.098 ± 0.5110 | -1.416 ± 0.3408 | -1.746 ± 0.3619 |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Change from Baseline was calculated from a rolling weekly average. A negative change from Baseline indicates improvement. LS means and standard errors were calculated from an ANCOVA with Baseline, treatment and stratum (Baseline vIGA-AD categories) in the model.
| score on a scale | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | -2.685 ± 0.9303 | -3.182 ± 1.2347 | -2.474 ± 0.3887 | -2.684 ± 0.4179 |
| Week 52 | -2.668 ± 1.2153 | -4.012 ± 1.3907 | -2.936 ± 0.4567 | -2.454 ± 0.4957 |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
| percentage of participants | Placebo / Risankizumab 150 mg | Placebo / Risankizumab 300 mg | Risankizumab 150 mg / Risankizumab 150 mg | Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|
| Week 28 | 22.2 (0.0 to 49.4) | 20.0 (0.0 to 55.1) | 31.3 (18.1 to 44.4) | 39.5 (24.9 to 54.1) |
| Week 52 | 20.0 (0.0 to 55.1) | 25.0 (0.0 to 67.4) | 38.2 (21.9 to 54.6) | 28.1 (12.5 to 43.7) |
Collected over From first dose of study drug up to 20 weeks after last dose. Period A: 16 weeks for participants who entered Period B or up to 36 weeks for participants who did not enter Period B. Period B: From Week 16 up to Week 60.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period A: Placebo | 1/34 (2.9%) | 3/34 (8.8%) | 17/34 (50%) |
| Period A: Risankizumab 150 mg | 0/69 (0%) | 0/69 (0%) | 25/69 (36.2%) |
| Period A: Risankizumab 300 mg | 0/69 (0%) | 0/69 (0%) | 25/69 (36.2%) |
| Period B: Placebo / Risankizumab 150 mg | 0/13 (0%) | 0/13 (0%) | 6/13 (46.2%) |
| Period B: Placebo / Risankizumab 300 mg | 0/11 (0%) | 0/11 (0%) | 5/11 (45.5%) |
| Period B: Risankizumab 150 mg / Risankizumab 150 mg | 0/61 (0%) | 2/61 (3.3%) | 13/61 (21.3%) |
| Period B: Risankizumab 300 mg / Risankizumab 300 mg | 0/57 (0%) | 3/57 (5.3%) | 10/57 (17.5%) |
| Event | Period A: Placebo | Period A: Risankizumab 150 mg | Period A: Risankizumab 300 mg | Period B: Placebo / Risankizumab 150 mg | Period B: Placebo / Risankizumab 300 mg | Period B: Risankizumab 150 mg / Risankizumab 150 mg | Period B: Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 1/34 | 0/69 | 0/69 | 0/13 | 0/11 | 0/61 | 0/57 |
| CERVIX CARCINOMA STAGE INeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/34 | 0/69 | 0/69 | 0/13 | 0/11 | 0/61 | 0/57 |
| DERMATITIS ATOPICSkin and subcutaneous tissue disorders | 1/34 | 0/69 | 0/69 | 0/13 | 0/11 | 0/61 | 0/57 |
| AMAUROSIS FUGAXEye disorders | 0/34 | 0/69 | 0/69 | 0/13 | 0/11 | 0/61 | 1/57 |
| CELLULITISInfections and infestations | 0/34 | 0/69 | 0/69 | 0/13 | 0/11 | 1/61 | 1/57 |
| FRACTURED COCCYXInjury, poisoning and procedural complications | 0/34 | 0/69 | 0/69 | 0/13 | 0/11 | 0/61 | 1/57 |
| SPINAL FRACTUREInjury, poisoning and procedural complications | 0/34 | 0/69 | 0/69 | 0/13 | 0/11 | 0/61 | 1/57 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 0/34 | 0/69 | 0/69 | 0/13 | 0/11 | 0/61 | 1/57 |
| ARRHYTHMIACardiac disorders | 0/34 | 0/69 | 0/69 | 0/13 | 0/11 | 1/61 | 0/57 |
| Event | Period A: Placebo | Period A: Risankizumab 150 mg | Period A: Risankizumab 300 mg | Period B: Placebo / Risankizumab 150 mg | Period B: Placebo / Risankizumab 300 mg | Period B: Risankizumab 150 mg / Risankizumab 150 mg | Period B: Risankizumab 300 mg / Risankizumab 300 mg |
|---|---|---|---|---|---|---|---|
| DERMATITIS ATOPICSkin and subcutaneous tissue disorders | 7/34 | 19/69 | 16/69 | 2/13 | 1/11 | 7/61 | 5/57 |
| TOOTHACHEGastrointestinal disorders | 0/34 | 0/69 | 1/69 | 0/13 | 2/11 | 0/61 | 0/57 |
| LEUKOPENIABlood and lymphatic system disorders | 0/34 | 1/69 | 0/69 | 0/13 | 1/11 | 1/61 | 0/57 |
| BUNDLE BRANCH BLOCK RIGHTCardiac disorders | 0/34 | 0/69 | 0/69 | 0/13 | 1/11 | 0/61 | 0/57 |
| DENTAL CARIESGastrointestinal disorders | 0/34 | 1/69 | 0/69 | 0/13 | 1/11 | 0/61 | 0/57 |
| TOOTH INFECTIONInfections and infestations | 0/34 | 0/69 | 0/69 | 0/13 | 1/11 | 0/61 | 1/57 |
| BLOOD THYROID STIMULATING HORMONE INCREASEDInvestigations | 0/34 | 0/69 | 0/69 | 0/13 | 1/11 | 0/61 | 0/57 |
| DIZZINESS POSTURALNervous system disorders | 0/34 | 0/69 | 0/69 | 0/13 | 1/11 | 0/61 | 0/57 |
| AMENORRHOEAReproductive system and breast disorders | 0/34 | 0/69 | 0/69 | 0/13 | 1/11 | 0/61 | 0/57 |
| HYPERTROPHIC SCARSkin and subcutaneous tissue disorders | 0/34 | 0/69 | 0/69 | 0/13 | 1/11 | 0/61 | 0/57 |
The intent-to-treat population includes all randomized participants
| Age, Continuous(years) | Placebo | Risankizumab 150 mg | Risankizumab 300 mg | Total |
|---|---|---|---|---|
| Mean | 45.5 ± 19.66 | 41.7 ± 15.12 | 43.8 ± 16.63 | 43.3 ± 16.66 |
| Age, Customized(Participants) | Placebo | Risankizumab 150 mg | Risankizumab 300 mg | Total |
|---|---|---|---|---|
| < 18 years | 0 | 1 | 1 | 2 |
| 18 - 39 years | 15 | 34 | 27 | 76 |
| 40 - 64 years | 10 | 27 | 36 | 73 |
| ≥ 65 years | 9 | 7 | 5 | 21 |
| Sex: Female, Male(Participants) | Placebo | Risankizumab 150 mg | Risankizumab 300 mg | Total |
|---|---|---|---|---|
| Female | 13 | 31 | 32 | 76 |
| Male | 21 | 38 | 37 | 96 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Risankizumab 150 mg | Risankizumab 300 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 8 | 6 | 14 |
| Not Hispanic or Latino | 34 | 61 | 63 | 158 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Risankizumab 150 mg | Risankizumab 300 mg | Total |
|---|---|---|---|---|
| White | 17 | 39 | 36 | 92 |
| Black or African American | 7 | 8 | 11 | 26 |
| Asian | 8 | 21 | 20 | 49 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 2 |
| American Indian or Alaska Native | 0 | 1 | 1 | 2 |
| Multiple | 1 | 0 | 0 | 1 |
| Geographic Region(Participants) | Placebo | Risankizumab 150 mg | Risankizumab 300 mg | Total |
|---|---|---|---|---|
| Japan | 6 | 13 | 13 | 32 |
| Rest of World | 28 | 56 | 56 | 140 |
| Disease Severity(Participants) | Placebo | Risankizumab 150 mg | Risankizumab 300 mg | Total |
|---|---|---|---|---|
| 3 (Moderate) | 20 | 40 | 39 | 99 |
| 4 (Severe) | 14 | 29 | 30 | 73 |
| Eczema Area and Severity Index (EASI) Score(score on a scale) | Placebo | Risankizumab 150 mg | Risankizumab 300 mg | Total |
|---|---|---|---|---|
| Mean | 30.85 ± 12.345 | 31.06 ± 13.995 | 28.70 ± 11.247 | 30.07 ± 12.605 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing, please refer to the link below.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · vivli.org
Ran from Dec 2018 to primary completion in Oct 2020, 22 months.
Results were first posted in Nov 2021, 1 year after primary completion.
Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 22 months is above that.
Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab